FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968207922> ?p ?o ?g. }

• W2968207922 endingPage "312" @default.
• W2968207922 startingPage "299" @default.
• W2968207922 abstract "Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM). Glucose metabolism has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells. However, few studies have focused on the effects of GEM on cancer cell metabolism, stemness of tumor cells, and molecular mechanisms that critically influence PanCa treatment. We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidation and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells. Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM’s cytotoxicity. GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift. GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness. In addition, GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway. This effect was validated by introducing exogenous hydrogen peroxide (H2O2). Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment. Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients. Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM). Glucose metabolism has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells. However, few studies have focused on the effects of GEM on cancer cell metabolism, stemness of tumor cells, and molecular mechanisms that critically influence PanCa treatment. We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidation and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells. Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM’s cytotoxicity. GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift. GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness. In addition, GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway. This effect was validated by introducing exogenous hydrogen peroxide (H2O2). Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment. Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients." @default.
• W2968207922 created "2019-08-22" @default.
• W2968207922 creator A5008953620 @default.
• W2968207922 creator A5011867023 @default.
• W2968207922 creator A5022057629 @default.
• W2968207922 creator A5028189969 @default.
• W2968207922 creator A5064989082 @default.
• W2968207922 creator A5066811658 @default.
• W2968207922 creator A5074753954 @default.
• W2968207922 creator A5083421260 @default.
• W2968207922 date "2019-09-01" @default.
• W2968207922 modified "2023-10-10" @default.
• W2968207922 title "ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer" @default.
• W2968207922 cites W1253008772 @default.
• W2968207922 cites W1910182523 @default.
• W2968207922 cites W1912771734 @default.
• W2968207922 cites W1965455284 @default.
• W2968207922 cites W1970766774 @default.
• W2968207922 cites W1975854213 @default.
• W2968207922 cites W1978763812 @default.
• W2968207922 cites W1981444673 @default.
• W2968207922 cites W1982165387 @default.
• W2968207922 cites W1982184962 @default.
• W2968207922 cites W1987855320 @default.
• W2968207922 cites W1997909566 @default.
• W2968207922 cites W2003048256 @default.
• W2968207922 cites W2003171202 @default.
• W2968207922 cites W2018026783 @default.
• W2968207922 cites W2021117623 @default.
• W2968207922 cites W2021251343 @default.
• W2968207922 cites W2023300506 @default.
• W2968207922 cites W2023947368 @default.
• W2968207922 cites W2029140945 @default.
• W2968207922 cites W2037619415 @default.
• W2968207922 cites W2045246542 @default.
• W2968207922 cites W2059022111 @default.
• W2968207922 cites W2061772840 @default.
• W2968207922 cites W2063018637 @default.
• W2968207922 cites W2069269337 @default.
• W2968207922 cites W2071798417 @default.
• W2968207922 cites W2087445490 @default.
• W2968207922 cites W2090485397 @default.
• W2968207922 cites W2097829773 @default.
• W2968207922 cites W2117692326 @default.
• W2968207922 cites W2117833492 @default.
• W2968207922 cites W2122339465 @default.
• W2968207922 cites W2127529642 @default.
• W2968207922 cites W2131170195 @default.
• W2968207922 cites W2141517721 @default.
• W2968207922 cites W2151260260 @default.
• W2968207922 cites W2157935510 @default.
• W2968207922 cites W2159104053 @default.
• W2968207922 cites W2161109457 @default.
• W2968207922 cites W2166087647 @default.
• W2968207922 cites W2175567961 @default.
• W2968207922 cites W2273522842 @default.
• W2968207922 cites W2314917154 @default.
• W2968207922 cites W2477699939 @default.
• W2968207922 cites W2494025241 @default.
• W2968207922 cites W2508385150 @default.
• W2968207922 cites W2512120066 @default.
• W2968207922 cites W2548539834 @default.
• W2968207922 cites W2550154271 @default.
• W2968207922 cites W2573963236 @default.
• W2968207922 cites W2594036641 @default.
• W2968207922 cites W2617805631 @default.
• W2968207922 doi "https://doi.org/10.1016/j.omto.2019.07.005" @default.
• W2968207922 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6726755" @default.
• W2968207922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31508487" @default.
• W2968207922 hasPublicationYear "2019" @default.
• W2968207922 type Work @default.
• W2968207922 sameAs 2968207922 @default.
• W2968207922 citedByCount "33" @default.
• W2968207922 countsByYear W29682079222020 @default.
• W2968207922 countsByYear W29682079222021 @default.
• W2968207922 countsByYear W29682079222022 @default.
• W2968207922 countsByYear W29682079222023 @default.
• W2968207922 crossrefType "journal-article" @default.
• W2968207922 hasAuthorship W2968207922A5008953620 @default.
• W2968207922 hasAuthorship W2968207922A5011867023 @default.
• W2968207922 hasAuthorship W2968207922A5022057629 @default.
• W2968207922 hasAuthorship W2968207922A5028189969 @default.
• W2968207922 hasAuthorship W2968207922A5064989082 @default.
• W2968207922 hasAuthorship W2968207922A5066811658 @default.
• W2968207922 hasAuthorship W2968207922A5074753954 @default.
• W2968207922 hasAuthorship W2968207922A5083421260 @default.
• W2968207922 hasBestOaLocation W29682079221 @default.
• W2968207922 hasConcept C121608353 @default.
• W2968207922 hasConcept C126322002 @default.
• W2968207922 hasConcept C1491633281 @default.
• W2968207922 hasConcept C184235292 @default.
• W2968207922 hasConcept C185592680 @default.
• W2968207922 hasConcept C24040308 @default.
• W2968207922 hasConcept C2776015282 @default.
• W2968207922 hasConcept C2778579378 @default.
• W2968207922 hasConcept C2779134260 @default.
• W2968207922 hasConcept C2780124434 @default.
• W2968207922 hasConcept C2780210213 @default.

• next